Patient Subgroups
EV-Pem had its best subgroup cost-effectiveness result in patients with high PD-L1 expression. EV-Pem performed worst in cisplatin-eligible patients because its incremental survival benefit was smallest relative to standard chemotherapy.
1 sources - 3 claims
EV-Pem had its best subgroup cost-effectiveness result in patients with high PD-L1 expression. EV-Pem performed worst in cisplatin-eligible patients because its incremental survival benefit was smallest relative to standard chemotherapy.